[go: up one dir, main page]

Esmon et al., 1995 - Google Patents

An update on clinical and basic aspects of the protein C anticoagulant pathway

Esmon et al., 1995

Document ID
4423743303985201109
Author
Esmon C
Schwarz H
Publication year
Publication venue
Trends in cardiovascular medicine

External Links

Snippet

The protein C anticoagulant pathway provides a mechanism for regulating the coagulation process through the selective inactivation of factors Va and VIIIa. Recent studies have suggested that factor V may facilitate this process and that a mutation at one of the …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Similar Documents

Publication Publication Date Title
Esmon et al. An update on clinical and basic aspects of the protein C anticoagulant pathway
Rapaport The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation
US5504064A (en) Treatment of bleeding with modified tissue factor in combination with an activator of FVII
Esmon et al. Regulation and functions of the protein C anticoagulant pathway
Rapaport et al. The tissue factor pathway: how it has become a “prima ballerina”
Taylor et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.
Rapaport Inhibition of factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a factor Xa-dependent inhibitory mechanism
Mann et al. Factor v: A combination of dr jekyll and mr hyde
Kalafatis et al. The regulation of clotting factors
JP3805981B2 (en) Methods for treating hypercoagulable states or acquired protein C deficiency
US5374617A (en) Treatment of bleeding with modified tissue factor in combination with FVIIa
US8715672B2 (en) Treatment of diseases linked to pathological kinin formation
JPH10502351A (en) Factors affecting thrombosis hemostasis
Kjalke et al. Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation
Ziedins et al. Factor VIIa replacement therapy in factor VII deficiency
WO1996013274A1 (en) Process for production of inhibited forms of activated blood factors
Griffin Control of coagulation reactions
Broze Jr Tissue factor pathway inhibitor and the revised hypothesis of blood coagulation
Minnema et al. The role of factor XI in coagulation: a matter of revision
US20050250688A1 (en) Methods for treating an ischemic disorder and improving stroke outcome
US5798332A (en) Glycosylation-mediated inhibition of factor X
Hirsh et al. C. Thrombogenesis
US6248548B1 (en) Thrombosis prophylaxis for factor Vleiden carriers
Warn-Cramer et al. Studies of factor Xa/phospholipid-induced intravascular coagulation in rabbits. Effects of immunodepletion of tissue factor pathway inhibitor.
US5187155A (en) Anticoagulant peptides